Article Type
Review
Published
This article reviews the cutaneous side effects of main molecularly targeted cancer therapies for solid tumors.
Review
This article reviews the cutaneous side effects of main molecularly targeted cancer therapies for solid tumors.
Review
This review provides an update on the current understanding, evaluation, and management of febrile seizures.
Editorial
This editorial describes the therapeutic achievements in the treatment of patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer.
Review
This review examines the therapeutic efficacy and safety of ezetimibe in combination therapy with statins and its potential side effects.
Review
Over the past ten years, sorafenib has been the only systemic agent approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) and in a second-line setting, most investigational drugs have failed to provide better survival outcomes than placebo. However, in 2016, data from the RESORCE trial, a phase 3 study evaluating regorafenib in HCC patients who experience disease progression after first-line treatment with sorafenib, have shown a 2.8-month median survival benefit over placebo (10.6 versus 7.8 months).